Nothing Special   »   [go: up one dir, main page]

US20060194241A1 - Lactobacillus specific probes - Google Patents

Lactobacillus specific probes Download PDF

Info

Publication number
US20060194241A1
US20060194241A1 US11/364,963 US36496306A US2006194241A1 US 20060194241 A1 US20060194241 A1 US 20060194241A1 US 36496306 A US36496306 A US 36496306A US 2006194241 A1 US2006194241 A1 US 2006194241A1
Authority
US
United States
Prior art keywords
seq
species
sequence complementary
oligonucleotide
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/364,963
Inventor
Jan Knol
Monique Haarman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060194241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia NV filed Critical Nutricia NV
Assigned to N.V. NUTRICIA reassignment N.V. NUTRICIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KNOL, JAN, HAARMAN, MONIQUE
Publication of US20060194241A1 publication Critical patent/US20060194241A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to probes and primers for quantification of Lactobacillus species.
  • the intestinal flora of human milk-fed infants is primarily composed of the genus Bifidobacterium and Lactobacillus .
  • the genera Bifidobacterium and Lactobacillus are considered to be important in maintaining a well-balanced intestinal microbiota and it has been postulated that they have several health-promoting effects.
  • Lactobacillus in general, i.e. on the genus level.
  • the genus Lactobacillus consists of many different species, which differ in metabolism, metabolites, enzyme activities, oligo- and polysaccharide utilisation, cell wall composition, and interaction with the host's immune system. It therefore can be expected that not every species of the genus Lactobacillus has the same functional effect on the infant.
  • Examples of different Lactobacillus species are L. rhamnosus, L. casei, L. paracasei, L. reuteri, L. fermentum, L. plantarum, L. acidophilus , and L. delbrueckii .
  • EP0674650 relates to nucleic acid sequences which preferentially bind to the rRNA or rDNA of microorganisms which cause the spoilage of beer.
  • the beer spoilage microorganisms are predominantly of the genera Lactobacillus and Pediococcus .
  • the nucleic acids may be used as probes in assays to detect the presence of these microorganisms. Kits containing two or more probes are also described.
  • a method of species-specifically detecting and quantitatively assaying species of the genus Lactobacillus found in humans, particularly human infants, as well as a diagnostic kit for the detection and quantification of Lactobacillus species is provided.
  • a method of species-specifically detecting and quantitatively assaying species of the genus Lactobacillus found in human faeces and/or intestine, particularly human infants, as well as a diagnostic kit for the detection and quantification of Lactobacillus species is provided.
  • Lactobacillus species especially those found in humans, i.e. L. acidophilus, L. casei, L. delbrueckii, L. fermentum. L. paracasei, L. plantarum, L. reuteri and L rhamnosus using species specific oligonucleotide primes and probes.
  • primers and probes can be used to identify species of Lactobacillus and Lactobacillus -like species via FISH, PCR, DGGE, TGGE, dot blot hybridisation and real time PCR methods. All these techniques have in common that it involves a hybridisation step with nucleotides. Preferably real time PCR is used to quantify Lactobacillus species.
  • Each of the sequences described below may have additional bases bonded to the 5′- or 3′-terminal thereof as long as it functions as a probe.
  • oligonucleotides can be prepared by conventional means for chemical synthesis, for example by an automated DNA synthesiser. DNA fragments containing the above-mentioned sequences can be prepared by enzymatic cleavage of genes from the corresponding Lactobacillus species.
  • Duplex 5′ nuclease assays were developed for L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantarum, L. reuteri and L rhamnosus as a proportion of the total cells of the genus Lactobacillus .
  • the choice for the intergenic spacer greatly depended on the fact that contamination and sensitivity issues were described for Real-Time PCR when 16S rDNA was used.
  • the overall conserved regions of the sequences were used to design primers and probes for the Lactobacillus genus.
  • TaqMan Minor groove Binding (MGB) probes were used.
  • conserved regions in the sequences of the different kind of subspecies, which showed little homology with other species were used to design primers and probes for respectively L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantaurum, L. rhamnosus and L. reuteri.
  • the primers and TaqMan MGB probes were designed with help of Primer Express 1.5a (Applied Biosystems, Nieuwerkerk a/d IJssel, N L). We applied the following criteria: The probe and primers should have a GC content of 30 to 80% and runs of more than 3 identically nucleotides (especially for guanidine (G)) should be avoided.
  • the melting temperature (Tm) of the probe should be between 68° C. and 70° C., whereas the primers should have a melting temperature 10° C. below the melting temperature of the probe. Furthermore, no G on the 5′ end of the probe should be present and the strand with more cytosine (C) than G was selected.
  • the last 5 nucleotides at the 3′ end of the primers should have no more than two G and/or C bases. Finally, the amplicon length should be less than 150 base pairs.
  • the designed primers and TaqMan MGB probes are shown in table 1 and were tested on specificity using the Basic Local Alignment Search Tool (BLAST).
  • the probe designed for the detection of the genus Lactobacillus consists of an oligonucleotide with the 5′ reporter dye VICTM (Applied Biosystems, NL) and the 3′ quencher NFQ-MGBTM (Applied Biosystems, NL) and the probes for the different Lactobacillus species of oligonucleotides with the 5′ reporter dye 6-carboxy-fluorescein (FAMTM) and the 3′ quencher NFQ-MGBTM (Applied Biosystems, NL).
  • FAMTM 6-carboxy-fluorescein
  • NFQ-MGBTM Applied Biosystems, NL
  • the universal probe consists of oligonucleotides with the 5′ reporter dye 6-carboxy-fluorescein (FAMTM) and the 3′ quencher dye 6-carboxy-tetramethyl-rhodamine (TAMRATM).
  • FAMTM reporter dye 6-carboxy-fluorescein
  • TAMRATM 3′ quencher dye 6-carboxy-tetramethyl-rhodamine
  • Table 1 Designed primers and probes for use in the 5′ nuclease assays. % Primers & Tm G BLAST ID Amplicon SEQ Target Probes Sequence (5′ ⁇ 3′) (° C.) C number length ID No L.
  • Labelled preparations are prepared by labelling the oligonucleotide with a detectable marker by conventional means.
  • Labelling markers which may be used include radioisotopes, fluorescent substances, enzymes, biotin and haptens.
  • Hybridisation between the labelled preparation and a sample can be performed in accordance with known techniques, such as dot blot hybridisation and northern hybridisation. The hybrid which are formed can be confirmed through the detection of the labelled preparation by known means, for example, autoradiography using radioisotopes, enzyme-labelled antibody techniques using enzyme or biotin, and the like.
  • the DNA fragments represented by SEQ ID selected from SEQ ID No 1, SEQ ID No 2, SEQ ID No 4, SEQ ID No 5, SEQ ID No 7, SEQ ID No 8, SEQ ID No 10, SEQ ID No 11, SEQ ID No 13, SEQ ID No 14, SEQ ID No 16, SEQ ID No 17, SEQ ID No 19, SEQ ID No 20, SEQ ID No 22, SEQ ID No 23, SEQ ID No 25, and SEQ ID No 26 respectively can be used as a primer in the PCR method for identification of species.
  • microbial cells to be identified are subjected to bacteriolysis, and any of the DNA fragments of SEQ ID No 1, SEQ ID No 4, SEQ ID No 7, SEQ ID No 10, SEQ ID No 13, SEQ ID No 16, SEQ ID No 19, SEQ ID No 22, SEQ ID No 25, respectively and SEQ ID selected from SEQ ID No 2, SEQ ID No 5, SEQ ID No 8, SEQ ID No 11, SEQ ID No 14, SEQ ID No 17, SEQ ID No 20, SEQ ID No 23, SEQ ID No 26, respectively is added thereto as a primer, followed by treatment with a DNA polymerase. If DNA amplification is observed using electrophoresis, etc., this means that the cells possess a gene portion which corresponds to the DNA fragment used, i.e. the cells are identified to be of the same species as the origin of the DNA fragment primer.
  • oligonucleotides comprising SEQ ID selected from SEQ ID No 1, SEQ ID No 2, SEQ ID No 4, SEQ ID No 5, SEQ ID No 7, SEQ ID No 8, SEQ ID No 10, SEQ ID No 11, SEQ ID No 13, SEQ ID No 14, SEQ ID No 16, SEQ ID No 17, SEQ ID No 19, SEQ ID No 20, SEQ ID No 22, SEQ ID No 23, SEQ ID No 25, SEQ ID No 26, and sequences complementary thereto.
  • oligonucleotide probe for detection of a nucleic acid target sequence which is characteristic of the species of the genus Lactobacillus , said probe being selected from:
  • a labelled oligonucleotide which specifically hybridises to Lactobacillus fermentum DNA represented by SEQ ID No 12 or a sequence complementary thereto;
  • the present invention also encompasses a method of species-specifically detecting species of the genus Lactobacillus found in human, particularly human infants, comprising the steps of:
  • the oligonucleotide probe above mentioned hybridises to the nucleic acid target sequence preferably the oligonucleotide probe is of SEQ ID No selected from SEQ ID No 3, SEQ ID No 6, SEQ ID No 9, SEQ ID No 12, SEQ ID No 15, SEQ ID No 18, SEQ ID No 21, SEQ ID No 24, SEQ ID No 27.
  • a diagnostic kit is herein provided for the detection in a sample of Lactobacillus species selected from L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantarum, L. reuteri and L. rhamnosus , by means of hybridisation analysis, comprising at least a DNA probe as mentioned above as well as one or more further means required for hybridisation analysis, such as denaturation liquid, a hybridisation liquid, a washing liquid, a solid carrier, a hybridisation vessel and label detecting means.
  • a diagnostic kit for the detection in a sample of the above-mentioned Lactobacillus species by means of PCR analysis comprising a set of DNA primers as mentioned above as well as one or more further means required for PCR analysis, such as a polymerase, a polymerisation liquid, an oil overlay, a reaction vessel and means for detecting the amplified DNA.
  • the diagnostic kit comprises at least a DNA probe as described above and a set of primers as described above and optionally further means as mentioned above.
  • the present probes and methods are particularly suitable for quantifying Lactobacillus on a species level in the intestine and/or faeces.
  • the probe and primers with SEQ ID 25, 26, and 27 are not related to specific Lactobacillus species but to the genus Lactobacillus .
  • SEQ ID 25, 26, 27 are used to quantify the genus Lactobacillus and to relate the quantity of specific Lactobacillus species to all lactobacilli .
  • SEQ ID NOs 1-24 are used for detecting and identifying a species and that SEQ ID NOs 25-27 are used for quantifying this identified species.
  • Lactobacillus species are quantified in infant faeces, since lactobacilli play an important role in the infants' health.
  • the results obtained from such an analysis can be used for selecting suitable Lactobacillus species as a probiotic supplement or probiotic food or component in a (helath) nutritional composition and/or selecting non-digestible saccharides selectively stimulating Lactobacillus species to be incorporated into a (health) nutritional composition.
  • These probiotics and/or prebiotics are preferably to be administered to the subject low in specific Lactobacillus species in order to rebalance the intestinal flora on a Lactobacillus species level and prevent or treat disorders associated with this imbalance.
  • the disorder is selected from the group consisting of allergy, atopic disease, eczema, diarrhoea, intestinal inflammation and infections.
  • the present probes and methods are preferably applied for selecting probiotics and/or non-digestible saccharides for administration to animals in order to promote animal health, more preferably the gastro-intestinal health of animals.
  • a method for preparing a nutritional composition comprising selecting suitable Lactobacillus species and/or selecting non-digestible saccharides selectively stimulating Lactobacillus species by applying the oligonucleotide probes according to the present invention and preferably the oligonucleotide primers according to the present invention, preferably in a method according to the present invention and incorporating said selected Lactobacillus species and/or non-digestible saccharides into a (health) nutritional composition.
  • the present probes and methods are preferably used for quantification and species determination of systemic infections by species from the genus Lactobacillus.
  • the present probes and methods are preferably used in controlling and/or monitoring food fermentation by Lactobacillus species.
  • Lactobacillus Strains Origin a Other Strains Origin a L. acidophilus ATCC 4356 Bacillus cereus ATCC 11778 ATCC 521 Bacteroides fragilis LMG 10263 T DSM 20079 T Brevibacterium casei ATCC 35513 T L. amylovorus DSM 20552 Clostridium difficile ATCC 9689 T L. bavaricus JCM 1128 Enterococcus feacalis DSM 20478 T L.
  • each duplex 5′ nuclease assay was tested by performing a 25 ⁇ l amplification of the different strains. These 25 ⁇ l PCR reactions were performed using 2.5 ⁇ l DNA template, 12.5 ⁇ l TaqMan Universal Master Mix (Applied Biosystems), optimised concentrations of the primers and probes (see table 3), followed by running the TaqMan Universal Temperature Profile, on the ABI Prism 7700 (Applied Biosystems, Nieuwerkerk a/d IJssel, N L).
  • 5′ nuclease assays were specific for the Lactobacillus species for which they were developed and the 5′nuclease assay for determination of the genus Lactobacillus detected all Lactobacillus species tested, but no other bacteria like Propionibacterium, Enterococcus or Pediococcus species.
  • the optimised concentrations of the primers and probes are given in table 3.
  • the CV values for reproducibility and repeatability for the different kind of 5′ nuclease assays were determined and can be found in table 4.
  • TABLE 3 Optimised final primer and probe concentrations used in the different duplex 5′ nuclease assays Forward Reverse Probe Target 5′ nuclease assay Primer (nM) Primer (nM) (nM) L. acidophilus L. acidophilus 900 900 200 Genus Lactobacillus 900 900 200 L. casei L. casei 900 900 200 Genus Lactobacillus 300 300 50 L. delbrueckii L. delbrueckii 300 300 100 Genus Lactobacillus 900 900 200 L.
  • fermentum L. fermentum 300 300 100 Genus Lactobacillus 300 300 100 L. paracasei L. paracasei 300 300 100 Genus Lactobacillus 300 300 100 L. plantarum L. plantarum 300 300 100 Genus Lactobacillus 300 300 100 L. reuteri L. reuteri 300 300 100 Genus Lactobacillus 900 900 200 L. rhamnosus L. rhamnosus 900 450 200 Genus Lactobacillus 150 100 100 Genus Genus Lactobacillus 600 600 100 Lactobacillus All bacteria 300 300 100 100
  • the developed and validated duplex 5′ nuclease assays show a good specificity, sensitivity, reproducibility and repeatability and can therefore be seen as a good tool for enumeration of the different Lactobacillus species in faeces or intestinal biopsies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pediatric Medicine (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein are sequence primers and probe for the detection of Lactobacillus species as well as diagnostic kit thereof.

Description

    TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to probes and primers for quantification of Lactobacillus species.
    • BACKGROUND OF THE INVENTION
  • Generally, the intestinal flora of human milk-fed infants is primarily composed of the genus Bifidobacterium and Lactobacillus. The genera Bifidobacterium and Lactobacillus are considered to be important in maintaining a well-balanced intestinal microbiota and it has been postulated that they have several health-promoting effects.
  • The approach up to now was to promote Lactobacillus in general, i.e. on the genus level. The genus Lactobacillus consists of many different species, which differ in metabolism, metabolites, enzyme activities, oligo- and polysaccharide utilisation, cell wall composition, and interaction with the host's immune system. It therefore can be expected that not every species of the genus Lactobacillus has the same functional effect on the infant. Examples of different Lactobacillus species are L. rhamnosus, L. casei, L. paracasei, L. reuteri, L. fermentum, L. plantarum, L. acidophilus, and L. delbrueckii. For example, species producing large amounts of D-lactate, such as L. delbrueckii, may cause acidosis in young infants. These results indicate that the stimulation of the genus Lactobacillus per se in the babies' colon may not be sufficient. It is therefore the aim to achieve a Lactobacillus flora in formula-fed infants that is reminiscent to the Lactobacillus flora of human milk fed babies on a species level.
  • So far, quantification of Lactobacillus on species level in faecal samples or intestinal biopsies has not been adequately performed. Plating, followed by colony determination and conventional PCR techniques only result in qualitative or semi-quantitative data. Fluorescence in situ hybridisation is not suitable, because of the low concentration of Lactobacillus species and the available FISH probes are not sufficiently specific.
  • Therefore, there is a need for a method to quantify Lactobacillus species distribution in the gastrointestinal tract and/or faeces of infants.
  • EP0674650 relates to nucleic acid sequences which preferentially bind to the rRNA or rDNA of microorganisms which cause the spoilage of beer. The beer spoilage microorganisms are predominantly of the genera Lactobacillus and Pediococcus. The nucleic acids may be used as probes in assays to detect the presence of these microorganisms. Kits containing two or more probes are also described.
    • SUMMARY OF THE INVENTION
  • In order to quantitatively determine the Lactobacillus species distribution in faeces real-time PCR (5′nuclease assay) has to be used, for which species specific probes and primers are provided.
  • A method of species-specifically detecting and quantitatively assaying species of the genus Lactobacillus found in humans, particularly human infants, as well as a diagnostic kit for the detection and quantification of Lactobacillus species is provided.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Probe Development and Diagnostic Kit
  • A method of species-specifically detecting and quantitatively assaying species of the genus Lactobacillus found in human faeces and/or intestine, particularly human infants, as well as a diagnostic kit for the detection and quantification of Lactobacillus species is provided.
  • Also provided herein is a method for quantifying Lactobacillus species, especially those found in humans, i.e. L. acidophilus, L. casei, L. delbrueckii, L. fermentum. L. paracasei, L. plantarum, L. reuteri and L rhamnosus using species specific oligonucleotide primes and probes.
  • These primers and probes can be used to identify species of Lactobacillus and Lactobacillus-like species via FISH, PCR, DGGE, TGGE, dot blot hybridisation and real time PCR methods. All these techniques have in common that it involves a hybridisation step with nucleotides. Preferably real time PCR is used to quantify Lactobacillus species.
  • Each of the sequences described below may have additional bases bonded to the 5′- or 3′-terminal thereof as long as it functions as a probe.
  • These oligonucleotides can be prepared by conventional means for chemical synthesis, for example by an automated DNA synthesiser. DNA fragments containing the above-mentioned sequences can be prepared by enzymatic cleavage of genes from the corresponding Lactobacillus species.
  • For the purpose of the present invention, the development of primers and probes specific to the Lactobacillus species for use in the 5′nuclease assay was as follows:
  • Duplex 5′ nuclease assays were developed for L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantarum, L. reuteri and L rhamnosus as a proportion of the total cells of the genus Lactobacillus. We developed the 5′ nuclease assays on the intergenic spacer of 16S-23S rDNA instead of the 16S rDNA gene, which is normally used for the phylogenetic analyses and specific detection of bacteria. The choice for the intergenic spacer greatly depended on the fact that contamination and sensitivity issues were described for Real-Time PCR when 16S rDNA was used. Furthermore, a large similarity between the 16S rDNA sequences of the different Lactobacillus species was shown (Leblond-Bourget et. al. 1996), which made it almost impossible to develop primer and probe sets specific for the different Lactobacillus species. Surprisingly, these problems could be avoided by using the intergenic spacer region.
  • For the development of primers and probes the different sequences of the 16S-23S intergenic spacer region of the different Lactobacillus species (L. acidophilus [AB102855 (3), AF182726 (5), U32971 (7)]a , L. amylovorus [AF182732 (5)], L. animalis [AY526616, AY526614], L. brevis [AB102858 (3), AF405353 (2)], L. bulgaricus [Z75475], L. casei [AB102854 (3), AF405352 (2), AF182729 (5), AF121200 (6)], L. collinoides [AB117957, AB117955], L. crispatus [AF182719 (5), AF074857 (6)], L. curvatus [AF074858 (6), U97135 (1), U97129 (1)], L. delbrueckii [AB102856 (3), AB035485 (5), AB035484 (5), U32969 (7), U32968 (7), U32967 (7)], L. farciminis [AF500491 (4), AF500490 (4)], L. fermentum [AF182720 (5)], L. frumenti [AJ616011], L. gasseri [AB102860 (3), AF182721 (5), AF074859 (6)], L. graminis [U97136 (1), U97130 (1)], L. hamsteri, L. helveticus [AF182728 (5)], L. jensenii [AB035486 (5), U32970 (7)], L. johnsonii [AF074860 (6)], L. mindensis [AJ616016], L. panis [AJ616012], L. paracasei [AB035487 (5), AF182724 (5), U32964 (7)], L. paralimentarius [AJ616014], L. paraplantarum [U97138 (1), U97132 (1)], L. pentosus [U97141 (1), U97140 (1), U97134 (1)], L. plantarum [AB102857 (3), AF405354 (2), AF182722 (5), U97139 (1), U97133 (1)], L. sakei [U97137 (1), U97131 (1)], L. salivarius [AB102859 (3), AB03488 (5), AF182725 (5)], L. sharpeae [AF074861 (6)], L. reuteri [AF182723 (5)], L. rhamnosus [AF182730 (5), AF121201 (6), U32966 (7)], L. ruminis [AF080103], L. vaginalis [AF182731], L. zeae [AF074862]a) were retrieved from Genbank, EMBL and DDBJ databases. All retrieved sequences were aligned using DNASIS for Windows V2.5 (Hitachi Software Engineering Co., Ltd., Wembley, UK). (a=accession codes, 1: Berthier et al. 1998. FEMS Microbiol Left 161:97-106. 2: Dobson et al. 2002. Int J Syst Evol Microbiol 52:2003-10. 3: Massi et al. 2004. J Appi Microbiol 96:777-86. 4: Rachman et al. 2003. J Appi Microbiol 95:1207-16. 5: Song et al. 2000. FEMS Microbiol Left 187:167-73. 6: Tannock et al. 1999 Appl Environ Microbiol 65:4264-7. 7: Tilsala-Timisjarvi, A., and T. Alatossava. 1997. Int J Food Microbiol 35:49-56.)
  • The overall conserved regions of the sequences were used to design primers and probes for the Lactobacillus genus. To increase specificity and sensitivity, TaqMan Minor groove Binding (MGB) probes were used. Conserved regions in the sequences of the different kind of subspecies, which showed little homology with other species were used to design primers and probes for respectively L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantaurum, L. rhamnosus and L. reuteri.
  • The primers and TaqMan MGB probes were designed with help of Primer Express 1.5a (Applied Biosystems, Nieuwerkerk a/d IJssel, N L). We applied the following criteria: The probe and primers should have a GC content of 30 to 80% and runs of more than 3 identically nucleotides (especially for guanidine (G)) should be avoided. The melting temperature (Tm) of the probe should be between 68° C. and 70° C., whereas the primers should have a melting temperature 10° C. below the melting temperature of the probe. Furthermore, no G on the 5′ end of the probe should be present and the strand with more cytosine (C) than G was selected. The last 5 nucleotides at the 3′ end of the primers should have no more than two G and/or C bases. Finally, the amplicon length should be less than 150 base pairs. The designed primers and TaqMan MGB probes are shown in table 1 and were tested on specificity using the Basic Local Alignment Search Tool (BLAST).
  • The probe designed for the detection of the genus Lactobacillus consists of an oligonucleotide with the 5′ reporter dye VIC™ (Applied Biosystems, NL) and the 3′ quencher NFQ-MGB™ (Applied Biosystems, NL) and the probes for the different Lactobacillus species of oligonucleotides with the 5′ reporter dye 6-carboxy-fluorescein (FAM™) and the 3′ quencher NFQ-MGB™ (Applied Biosystems, NL). For determination of the total bacterial load a broad-range (universal probe and primer set is used, which is described by Nadkarni, et al, 2002, Microbiology 148:257-266. The universal probe consists of oligonucleotides with the 5′ reporter dye 6-carboxy-fluorescein (FAM™) and the 3′ quencher dye 6-carboxy-tetramethyl-rhodamine (TAMRA™). The designed probes are shown in table 1.
    TABLE 1
    Designed primers and probes for use in the 5′ nuclease assays.
    %
    Primers & Tm G BLAST ID Amplicon SEQ
    Target Probes Sequence (5′ → 3′) (° C.) C number length ID No
    L. acido- F_acid_IS GAAAGAGCCCAAAC 59 43 1089017502- 85 1
    philus CAAGTGATT 26171-
    2029659558
    40
    R_acid_IS CTTCCCAGATAATT 59 37 1089017571- 2
    CAACTATCGCTTA 27139-
    5254509477
    P_acid_IS TACCACTTTGCA 70 45 2 3
    GTCCTACA 1089017717-
    29310-
    1542960554
    15
    L. casei F_case_IS CTATAAGTAAGCTTT 59 36 1037022798- 132 4
    GATCCGGAGATTT 023495-2136
    R_case_IS CTTCCTGCGGGTAC 59 55 1037022917- 5
    TGAGATGT 024843-
    29627
    P_case_IS ACAAGCTATGAATT 70 38 1037022752- 6
    CACT TGC 023005-
    20772
    L. del- F_delb_IS CACTTGTACGTTGA 58 30 1089018504- 94 7
    brueckii AAACTGAATATCTTA 4206-
    Aa 6452981190
    6
    R_delb_IS CGAACTCTCTCGGT 58 55 1089018475- 8
    CGCTTT 6841-
    1666577681
    51
    P_delb_IS CCGAGAATCATTGA 68 44 1089018437- 9
    GATC 6309-
    1639882274
    98
    L. fer- F_ferm_IS AACCGAGAACACCG 58 50 1036676682- 88 10
    mentum CGTTAT 09669-23287
    R_ferm_IS ACTTAACCTTACTGA 58 38 1036676709- 11
    TCGTAGATCAGTCA 010209-2351
    P_ferm_IS TAATCGCATACTCA 68 32 1036676736- 12
    ACTAA 010547-
    20717
    L. para- F_paca_IS ACATCAGTGTATTG 60 38 1038306417- 80 13
    casei CTTGTCAGTGAATA 016220-
    C 23561
    R_paca_IS CCTGCGGGTACTGA 60 55 103806445- 14
    GATG TTTC 016796-3050
    P_paca_IS TGCCGCCGGCCAG 70 85 1038306524- 15
    018375-2626
    L. F_plan_IS TGGATCACCTCCTT 58 42 1038305707- 144 16
    planta- TCTAAGGAAT 03107-18756
    rum
    R_plan_IS TGTTCTCGGTTTCAT 58 26 1038305742- 17
    TATGAAAAAATAa 04177-12861
    P_plan_IS ACATTCTTCGAAACT 68 32 1038305778- 18
    TTGT 04682-12880
    L. F_reut_IS ACCGAGAACACCGC 59 48 1089025339- 93 19
    reuteri GTTATTT 29395-
    1292800472
    16
    R_reut_IS CATAACTTAACCTAA 59 28 1089025385- 20
    ACAATCAAAGAT 30347-
    TGTCT 3755823275
    4
    P_reut_IS ATCGCTAACTCAATT 69 28 1089025413- 21
    AAT 30287-
    2611284585
    4
    L. F_rham_IS CGGCTGGATCACCT 59 58 1023708254- 97 22
    rhamno- CCTTT 09591-2284
    sus
    R_rham_IS GCTTGAGGGTAATC 59 52 1023708352- 23
    CCCT CAA 010389-
    16127
    P_rham_IS CCTGCACACACGAA 69 55 1023708453- 24
    A 011313-6655
    Genus F_alliact_IS TGGATGCCTTGGCA 58 55 1024485925- 92 25
    Lacto- CTAGGA 024664-
    bacillus 30598
    R_alliact_IS AAATCTCCGGATCA 58 35 1024478788- 26
    AAGCTTACTTAT 024701-
    16287
    P_alliact_IS TATTAGTTCCGTCCT 68 40 1024478009- 27
    TCATC 017753-
    28422
    All F_eub TCCTACGGGAGGCA 59 Nadkarni et. 466 bpa
    bacteria GCAGT al. 2002
    R_eub GGACTACCAGGGTA 58
    TCTAATCCTGTT
    P_eub CGTATTACCGCGGC 70
    TGCTGGCAC

    aIn these cases some adjustments (more than 3 consecutive nucleotides or an amplicon length greater then 150 bp) were made to the guidelines to find an appropriate primer and probe set.
  • Labelled preparations are prepared by labelling the oligonucleotide with a detectable marker by conventional means. Labelling markers which may be used include radioisotopes, fluorescent substances, enzymes, biotin and haptens. Hybridisation between the labelled preparation and a sample can be performed in accordance with known techniques, such as dot blot hybridisation and northern hybridisation. The hybrid which are formed can be confirmed through the detection of the labelled preparation by known means, for example, autoradiography using radioisotopes, enzyme-labelled antibody techniques using enzyme or biotin, and the like.
  • Further, of these oligonucleotides, the DNA fragments represented by SEQ ID selected from SEQ ID No 1, SEQ ID No 2, SEQ ID No 4, SEQ ID No 5, SEQ ID No 7, SEQ ID No 8, SEQ ID No 10, SEQ ID No 11, SEQ ID No 13, SEQ ID No 14, SEQ ID No 16, SEQ ID No 17, SEQ ID No 19, SEQ ID No 20, SEQ ID No 22, SEQ ID No 23, SEQ ID No 25, and SEQ ID No 26 respectively can be used as a primer in the PCR method for identification of species. More specifically, microbial cells to be identified are subjected to bacteriolysis, and any of the DNA fragments of SEQ ID selected from SEQ ID No 1, SEQ ID No 4, SEQ ID No 7, SEQ ID No 10, SEQ ID No 13, SEQ ID No 16, SEQ ID No 19, SEQ ID No 22, SEQ ID No 25, respectively and SEQ ID selected from SEQ ID No 2, SEQ ID No 5, SEQ ID No 8, SEQ ID No 11, SEQ ID No 14, SEQ ID No 17, SEQ ID No 20, SEQ ID No 23, SEQ ID No 26, respectively is added thereto as a primer, followed by treatment with a DNA polymerase. If DNA amplification is observed using electrophoresis, etc., this means that the cells possess a gene portion which corresponds to the DNA fragment used, i.e. the cells are identified to be of the same species as the origin of the DNA fragment primer.
  • Accordingly, there are provided oligonucleotides comprising SEQ ID selected from SEQ ID No 1, SEQ ID No 2, SEQ ID No 4, SEQ ID No 5, SEQ ID No 7, SEQ ID No 8, SEQ ID No 10, SEQ ID No 11, SEQ ID No 13, SEQ ID No 14, SEQ ID No 16, SEQ ID No 17, SEQ ID No 19, SEQ ID No 20, SEQ ID No 22, SEQ ID No 23, SEQ ID No 25, SEQ ID No 26, and sequences complementary thereto.
  • Also provided herein are oligonucleotide probe for detection of a nucleic acid target sequence which is characteristic of the species of the genus Lactobacillus, said probe being selected from:
  • 1)-a labelled oligonucleotide which specifically hybridises to Lactobacillus acidophilus DNA represented by SEQ ID No 3 or a sequence complementary thereto;
  • 2)-a labelled oligonucleotide which specifically hybridises to Lactobacillus casei DNA represented by SEQ ID No 6 or a sequence complementary thereto;
  • 3)-a labelled oligonucleotide which specifically hybridises to Lactobacillus delbrueckii DNA represented by SEQ ID No 9 or a sequence complementary thereto;
  • 4)-a labelled oligonucleotide which specifically hybridises to Lactobacillus fermentum DNA represented by SEQ ID No 12 or a sequence complementary thereto;
  • 5)-a labelled oligonucleotide which specifically hybridises to Lactobacillus paracasei DNA represented by SEQ ID No 15 or a sequence complementary thereto;
  • 6)-a labelled oligonucleotide which specifically hybridises to Lactobacillus plantarum DNA represented by SEQ ID No 18 or a sequence complementary thereto;
  • 7)-a labelled oligonucleotide which specifically hybridises to Lactobacillus reuteri DNA represented by SEQ ID No 21 or a sequence complementary thereto;
  • 8)-a labelled oligonucleotide which specifically hybridises to Lactobacillus rhamnosus DNA represented by SEQ ID No 24 or a sequence complementary thereto;
  • 9)-a labelled oligonucleotide which specifically hybridises to Lactobacillus DNA represented by SEQ ID No 27 or a sequence complementary thereto.
  • Further provided herein is a method of species-specifically detecting species of the genus Lactobacillus found in human, particularly human infants, comprising the steps of:
  • (A) contacting a sample with an oligonucleotide probe in a hybridising solution, wherein said probe is selected from the group consisting of:
  • 1) a labelled oligonucleotide which specifically hybridises to Lactobacillus acidophilus DNA represented by SEQ ID No 3 or a sequence complementary thereto;
  • 2) a labelled oligonucleotide which specifically hybridises to Lactobacillus casei DNA represented by SEQ ID No 6 or a sequence complementary thereto;
  • 3) a labelled oligonucleotide which specifically hybridises to Lactobacillus delbrueckii DNA represented by SEQ ID No 9 or a sequence complementary thereto;
  • 4) a labelled oligonucleotide which specifically hybridises to Lactobacillus fermentum DNA represented by SEQ ID No 12 or a sequence complementary thereto;
  • 5) a labelled oligonucleotide which specifically hybridises to Lactobacillus paracasei DNA represented by SEQ ID No 15 or a sequence complementary thereto;
  • 6) a labelled oligonucleotide which specifically hybridises to Lactobacillus plantarum DNA represented by SEQ ID No 18 or a sequence complementary thereto;
  • 7) a labelled oligonucleotide which specifically hybridises to Lactobacillus reuteri DNA represented by SEQ ID No 21 or a sequence complementary thereto;
  • 8) a labelled oligonucleotide which specifically hybridises to Lactobacillus rhamnosus DNA represented by SEQ ID No 24 or a sequence complementary thereto;
  • 9) a labelled oligonucleotide which specifically hybridises to all Lactobacillus DNA represented by SEQ ID No 27 or a sequence complementary thereto, and
  • (B) determining whether said probe hybridises to nucleic acids in said sample so as to detect whether said species of said genus is present in said sample.
  • The present invention also encompasses a method of species-specifically detecting species of the genus Lactobacillus found in human, particularly human infants, comprising the steps of:
  • a) performing a nucleic acid sequence amplification procedure using a primer set comprising the oligonucleotide primer of SEQ ID No selected from SEQ ID No 1, SEQ ID No 4, SEQ ID No 7, SEQ ID No 10, SEQ ID No 13, SEQ ID No 16, SEQ ID No 19, SEQ ID No 22, SEQ ID No 25, and respectively with the oligonucletide primer of SEQ ID selected from SEQ ID No 2, SEQ ID No 5, SEQ ID No 8, SEQ ID No 11, SEQ ID No 14, SEQ ID No 17, SEQ ID No 20, SEQ ID No 23, SEQ ID No 26; and
  • b) determining whether the oligonucleotide probe above mentioned hybridises to the nucleic acid target sequence, preferably the oligonucleotide probe is of SEQ ID No selected from SEQ ID No 3, SEQ ID No 6, SEQ ID No 9, SEQ ID No 12, SEQ ID No 15, SEQ ID No 18, SEQ ID No 21, SEQ ID No 24, SEQ ID No 27.
  • The present method is beneficial for the manufacture of a diagnostic kit. Accordingly, a diagnostic kit is herein provided for the detection in a sample of Lactobacillus species selected from L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantarum, L. reuteri and L. rhamnosus, by means of hybridisation analysis, comprising at least a DNA probe as mentioned above as well as one or more further means required for hybridisation analysis, such as denaturation liquid, a hybridisation liquid, a washing liquid, a solid carrier, a hybridisation vessel and label detecting means. Also herein provided is a diagnostic kit for the detection in a sample of the above-mentioned Lactobacillus species by means of PCR analysis, comprising a set of DNA primers as mentioned above as well as one or more further means required for PCR analysis, such as a polymerase, a polymerisation liquid, an oil overlay, a reaction vessel and means for detecting the amplified DNA. In one embodiment the diagnostic kit comprises at least a DNA probe as described above and a set of primers as described above and optionally further means as mentioned above.
  • The present probes and methods are particularly suitable for quantifying Lactobacillus on a species level in the intestine and/or faeces. The probe and primers with SEQ ID 25, 26, and 27 are not related to specific Lactobacillus species but to the genus Lactobacillus. SEQ ID 25, 26, 27 are used to quantify the genus Lactobacillus and to relate the quantity of specific Lactobacillus species to all lactobacilli. Thus it may be said that SEQ ID NOs 1-24 are used for detecting and identifying a species and that SEQ ID NOs 25-27 are used for quantifying this identified species. Preferably Lactobacillus species are quantified in infant faeces, since lactobacilli play an important role in the infants' health. The results obtained from such an analysis can be used for selecting suitable Lactobacillus species as a probiotic supplement or probiotic food or component in a (helath) nutritional composition and/or selecting non-digestible saccharides selectively stimulating Lactobacillus species to be incorporated into a (health) nutritional composition. These probiotics and/or prebiotics are preferably to be administered to the subject low in specific Lactobacillus species in order to rebalance the intestinal flora on a Lactobacillus species level and prevent or treat disorders associated with this imbalance. Preferably, the disorder is selected from the group consisting of allergy, atopic disease, eczema, diarrhoea, intestinal inflammation and infections. Likewise, the present probes and methods are preferably applied for selecting probiotics and/or non-digestible saccharides for administration to animals in order to promote animal health, more preferably the gastro-intestinal health of animals. Thus a method for preparing a nutritional composition is provided, said method comprising selecting suitable Lactobacillus species and/or selecting non-digestible saccharides selectively stimulating Lactobacillus species by applying the oligonucleotide probes according to the present invention and preferably the oligonucleotide primers according to the present invention, preferably in a method according to the present invention and incorporating said selected Lactobacillus species and/or non-digestible saccharides into a (health) nutritional composition.
  • The present probes and methods are preferably used for quantification and species determination of systemic infections by species from the genus Lactobacillus.
  • The present probes and methods are preferably used in controlling and/or monitoring food fermentation by Lactobacillus species.
    • EXAMPLE
  • Validation and Optimisation of the Developed Probes and Primers for Lactobacilli
  • The bacterial strains used to validate the assays for the relative quantification of the different Lactobacillus species are listed in Table 2.
    TABLE 2
    Bacterial strains (origin) used in this study.
    Lactobacillus
    Strains Origina Other Strains Origina
    L. acidophilus ATCC 4356 Bacillus cereus ATCC 11778
    ATCC 521 Bacteroides fragilis LMG 10263T
    DSM 20079T Brevibacterium casei ATCC 35513T
    L. amylovorus DSM 20552 Clostridium difficile ATCC 9689T
    L. bavaricus JCM 1128 Enterococcus feacalis DSM 20478T
    L. brevis LMG 18022 Escherichia coli ATCC 35218
    L. bulgaricus ATCC 11842T Listeria ATCC 7644
    monocytogenes
    L. casei ATCC 393T Pediococcus DSM 20284T
    acidilactici
    DSM 20011T Propionibacterium DSM 4901
    avidum
    L. crispatus ATCC 33820T Pseudomonas DSM 1117
    aeruginosa
    L. curvatus ATCC 51436 Saccharomyces DSM 2548
    cerevisiae
    L. delbrueckii JCM 1106 Salmonella ATCC 14028
    typhimurium
    JCM 1248T Staphylococcus aureus ATCC 29213
    L. fermentum DSM 20052T Bifidobacterium ATCC 15703T
    adolescentis
    L. gasseri LMG 11496T Bifidobacterium DSM 20098T
    angulatum
    Bifidobacterium DSM 20456T
    bifidum
    L. helveticus CNRZ 32 Bifidobacterium ATCC 25527T
    animalis
    L. johnsonii ATCC 33200T Bifidobacterium DSM 20093T
    gallicum
    L. kefir LMG 11496 Bifidobacterium ATCC 27534T
    dentium
    L. kefirgranum DSM 10550T Bifidobacterium breve ATCC 15700T
    L. paracasei ATCC 11582 Bifidobacterium ATCC 27539T
    catenulatum
    ATCC 27216 Bifidobacterium LMG 8811T
    infantis
    L. pentosus JCM 8334 Bifidobacterium ATCC 15707T
    JCM 8338 longum
    L. plantarum DSM 20174T
    NCIMB 8826
    L. reuteri LMG 9213T
    L. rhamnosus ATCC 53103
    ATCC 7469T
    L. sake DSM 6333
    L. salivarius ATCC 11741T

    aATCC: American Type Culture Collection; CNRZ: Centre National de Recerches Zootechniques, France; DSM: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany; JCM: Japan Collection of Microorganisms, Japan; LMG: Laboratory for Microbiology, University of Gent, Belgium; NCIMB: National Collections of Industrial and Marine Bacteria, UK;

    TType strain
  • All strains of lactobacilli, bifidobacteria, propionibacteria, enterococci, pediococci and Saccharomyces were cultured overnight under suitable conditions stored at −20° C. DNA was extracted by thawing 5 ml of frozen overnight cultures by methods known in the art and stored at −20° C.
  • The specificity of each duplex 5′ nuclease assay was tested by performing a 25 μl amplification of the different strains. These 25 μl PCR reactions were performed using 2.5 μl DNA template, 12.5 μl TaqMan Universal Master Mix (Applied Biosystems), optimised concentrations of the primers and probes (see table 3), followed by running the TaqMan Universal Temperature Profile, on the ABI Prism 7700 (Applied Biosystems, Nieuwerkerk a/d IJssel, N L). All of the 5′ nuclease assays were specific for the Lactobacillus species for which they were developed and the 5′nuclease assay for determination of the genus Lactobacillus detected all Lactobacillus species tested, but no other bacteria like Propionibacterium, Enterococcus or Pediococcus species.
  • The optimised concentrations of the primers and probes are given in table 3. The CV values for reproducibility and repeatability for the different kind of 5′ nuclease assays were determined and can be found in table 4.
    TABLE 3
    Optimised final primer and probe concentrations used in the different
    duplex 5′ nuclease assays
    Forward Reverse Probe
    Target 5′ nuclease assay Primer (nM) Primer (nM) (nM)
    L. acidophilus L. acidophilus 900 900 200
    Genus Lactobacillus 900 900 200
    L. casei L. casei 900 900 200
    Genus Lactobacillus 300 300 50
    L. delbrueckii L. delbrueckii 300 300 100
    Genus Lactobacillus 900 900 200
    L. fermentum L. fermentum 300 300 100
    Genus Lactobacillus 300 300 100
    L. paracasei L. paracasei 300 300 100
    Genus Lactobacillus 300 300 100
    L. plantarum L. plantarum 300 300 100
    Genus Lactobacillus 300 300 100
    L. reuteri L. reuteri 300 300 100
    Genus Lactobacillus 900 900 200
    L. rhamnosus L. rhamnosus 900 450 200
    Genus Lactobacillus 150 100 100
    Genus Genus Lactobacillus 600 600 100
    Lactobacillus All bacteria 300 300 100
  • TABLE 4
    The CV values for reproducibility and repeatability of the
    5′ nuclease assays
    Target Reproducibilitya (CV) Repeatabilityb (CV)
    L. acidophilus 0.109 0.127
    L. casei 0.058 0.063
    L. delbrueckii 0.059 0.035
    L. fermentum 0.067 0.048
    L. paracasei 0.052 0.110
    L. plantarum 0.134 0.135
    L. reuteri 0.062 0.113
    L. rhamnosus 0.047 0.053

    areproducibility is determined by testing monocultures (100%) in ten fold and calculation of the CV (%) based on the gained results

    brepeatability is determined by testing monocultures (100%) three times in four fold and calculation of the CV (%) based on results gained.
  • The developed and validated duplex 5′ nuclease assays show a good specificity, sensitivity, reproducibility and repeatability and can therefore be seen as a good tool for enumeration of the different Lactobacillus species in faeces or intestinal biopsies.

Claims (9)

1. Oligonucleotides comprising SEQ ID selected from SEQ ID No 1, SEQ ID No 2, SEQ ID No 4, SEQ ID No 5, SEQ ID No 7, SEQ ID No 8, SEQ ID No 10, SEQ ID No 11, SEQ ID No 13, SEQ ID No 14, SEQ ID No 16, SEQ ID No 17, SEQ ID No 19, SEQ ID No 20, SEQ ID No 22, SEQ ID No 23, SEQ ID No 25, SEQ ID No 26, and sequences complementary thereto.
2. Oligonucleotide probe for detection of a nucleic acid target sequence which is characteristic of the species of the genus Lactobacillus, said probe being selected from:
1) a labelled oligonucleotide which specifically hybridises to L. acidophilus DNA represented by SEQ ID No 3 or a sequence complementary thereto;
2) a labelled oligonucleotide which specifically hybridises to L. casei DNA represented by SEQ ID No 6 or a sequence complementary thereto;
3) a labelled oligonucleotide which specifically hybridises to L. delbrueckii DNA represented by SEQ ID No 9 or a sequence complementary thereto;
4) a labelled oligonucleotide which specifically hybridises to L. fermentum DNA represented by SEQ ID No 12 or a sequence complementary thereto;
5) a labelled oligonucleotide which specifically hybridises to L. paracasei DNA represented by SEQ ID No 15 or a sequence complementary thereto;
6) a labelled oligonucleotide which specifically hybridises to L. plantarum DNA represented by SEQ ID No 18 or a sequence complementary thereto;
7) a labelled oligonucleotide which specifically hybridises to L. reuteri DNA represented by SEQ ID No 21 or a sequence complementary thereto;
8) a labelled oligonucleotide which specifically hybridises to L. rhamnosus DNA represented by SEQ ID No 24 or a sequence complementary thereto;
9) a labelled oligonucleotide which specifically hybridises to the genus Lactobacillus DNA represented by SEQ ID No 27 or a sequence complementary thereto.
3. A method of species-specifically detecting species of the genus Lactobacillus found in human, particularly human infants, comprising the steps of:
(A) contacting a sample with an oligonucleotide probe in a hybridising solution, wherein said probe is selected from the group consisting of:
1) a labelled oligonucleotide which specifically hybridises to L. acidophilus DNA represented by SEQ ID No 3 or a sequence complementary thereto;
2) a labelled oligonucleotide which specifically hybridises to L. casei DNA represented by SEQ ID No 6 or a sequence complementary thereto;
3) a labelled oligonucleotide which specifically hybridises to L. delbrueckii DNA represented by SEQ ID No 9 or a sequence complementary thereto;
4) a labelled oligonucleotide which specifically hybridises to L. fermentum DNA represented by SEQ ID No 12 or a sequence complementary thereto;
5) a labelled oligonucleotide which specifically hybridises to L. paracasei DNA represented by SEQ ID No 15 or a sequence complementary thereto;
6) a labelled oligonucleotide which specifically hybridises to L. plantarum DNA represented by SEQ ID No 18 or a sequence complementary thereto;
7) a labelled oligonucleotide which specifically hybridises to L. reuteri DNA represented by SEQ ID No 21 or a sequence complementary thereto;
8) a labelled oligonucleotide which specifically hybridises to L. rhamnosus DNA represented by SEQ ID No 24 or a sequence complementary thereto;
9) a labelled oligonucleotide which specifically hybridises to the genus Lactobacillus DNA represented by SEQ ID No 27 or a sequence complementary thereto; and
(B) determining whether said probe hybridises to nucleic acids in said sample so as to detect whether said species of said genus is present in said sample.
4. A method of species-specifically quantifying the detected species of the genus Lactobacillus found in humans, particularly in human faeces, according to claim 3, wherein said quantifying method is real time PCR.
5. A method of species-specifically detecting species of the genus Lactobacillus found in human, particularly human infants, comprising the steps of:
a) performing a nucleic acid sequence amplification procedure using a primer set comprising the oligonucleotide primer of claim 1, preferably the oligonucleotide primer of SEQ ID No selected from SEQ ID No 1, SEQ ID No 4, SEQ ID No 7, SEQ ID No 10, SEQ ID No 13, SEQ ID No 16, SEQ ID No 19, SEQ ID No 22, SEQ ID No 25, and respectively with the oligonucleotide primer of SEQ ID selected from SEQ ID No 2, SEQ ID No 5, SEQ ID No 8, SEQ ID No 11, SEQ ID No 14, SEQ ID No 17, SEQ ID No 20, SEQ ID No 23, SEQ ID No 26; and
b) determining whether an oligonucleotide probe of claim 2, preferably respectively the oligonucleotide probe of SEQ ID No selected from SEQ ID No 3, SEQ ID No 6, SEQ ID No 9, SEQ ID No 12, SEQ ID No 15, SEQ ID No 18, SEQ ID No 21, SEQ ID No 24, SEQ ID No 27, hybridises to a nucleic acid target sequence.
6. A diagnostic kit for the detection in a sample of Lactobacillus species selected from L. acidophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei. L. plantarum, L. reuteri, and L. rhamnosus, by means of hybridisation analysis, comprising at least a DNA probe according to claim 2 as well as one or more further means required for hybridisation analysis, such as denaturation liquid, a hybridisation liquid, a washing liquid, a solid carrier, a hybridisation vessel and label detecting means.
7. A diagnostic kit for the detection in a sample of Lactobacillus species selected from L. acodophilus, L. casei, L. delbrueckii, L. fermentum, L. paracasei, L. plantarum, L. reuteri, and L. rhamnosus by means of PCR analysis, comprising a set of DNA primers according to claim 1 as well as one or more further means required for PCR analysis, such as a polymerase, a polymerisation liquid, an oil overlay, a reaction vessel and means for detecting the amplified DNA.
8. Use of the oligonucleotide sequences and methods of any of the preceding claims for quantifying Lactobacillus species in faeces.
9. Use of the oligonucleotide sequences and methods of any of the preceding claims for selecting Lactobacillus species and/or non-digestible saccharides selectively stimulating the growth of Lactobacillus species, to be incorporated into a nutritional composition.
US11/364,963 2005-02-28 2006-02-28 Lactobacillus specific probes Abandoned US20060194241A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075486 2005-02-28
EP05075486.0 2005-02-28

Publications (1)

Publication Number Publication Date
US20060194241A1 true US20060194241A1 (en) 2006-08-31

Family

ID=35229644

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/817,102 Active 2031-08-08 US9314047B2 (en) 2005-02-28 2006-02-28 Nutritional composition with probiotics
US11/364,963 Abandoned US20060194241A1 (en) 2005-02-28 2006-02-28 Lactobacillus specific probes
US15/088,639 Active 2026-03-07 US10071125B2 (en) 2005-02-28 2016-04-01 Nutritional composition with probiotics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/817,102 Active 2031-08-08 US9314047B2 (en) 2005-02-28 2006-02-28 Nutritional composition with probiotics

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/088,639 Active 2026-03-07 US10071125B2 (en) 2005-02-28 2016-04-01 Nutritional composition with probiotics

Country Status (16)

Country Link
US (3) US9314047B2 (en)
EP (3) EP2805625B2 (en)
CN (2) CN101128129A (en)
AT (1) ATE526836T1 (en)
AU (1) AU2006217160B2 (en)
BR (1) BRPI0607743B1 (en)
CA (1) CA2598961C (en)
DK (2) DK1855550T3 (en)
ES (3) ES2373971T3 (en)
MX (1) MX2007010466A (en)
PL (3) PL2351492T3 (en)
PT (2) PT1855550E (en)
RU (2) RU2422025C2 (en)
TR (1) TR201820329T4 (en)
WO (1) WO2006091103A2 (en)
ZA (1) ZA200706875B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063002A1 (en) * 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
US20110014167A1 (en) * 2007-07-06 2011-01-20 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US20120269789A1 (en) * 2009-05-11 2012-10-25 Nestec S.A. Growing up milks containing probiotic micro-organisms
CN103054048A (en) * 2005-12-23 2013-04-24 纽崔西亚公司 Infant nutritional compositions for preventing obesity

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
DK1800675T3 (en) * 2005-12-23 2011-09-05 Nutricia Nv Compositions comprising polyunsaturated fatty acids, proteins and manganese and / or molybdenum and nucleosides / nucleotides for the treatment of dementia
JP2009067679A (en) * 2005-12-27 2009-04-02 Univ Of Tokushima Pharmaceutical having anti-histamine activity
PT2164349E (en) 2006-08-04 2014-12-11 Shs Int Ltd Protein free formula
US20080254166A1 (en) * 2007-01-25 2008-10-16 Potter Susan M Food Additives Containing Combinations of Prebiotics and Probiotics
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
WO2008156354A1 (en) * 2007-06-21 2008-12-24 N.V. Nutricia Modulation of intestinal flora of hiv patients
EP2170088A2 (en) * 2007-06-27 2010-04-07 Chr. Hansen A/S Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
JP2009057346A (en) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd Composition for regulating immune balance
EP2631650B1 (en) 2007-09-07 2015-04-22 Children's Hospital Medical Center Composition comprising alpha-1,2 fucosyl glycans for treating gastrointestinal disorders
PT2190304E (en) * 2007-09-17 2012-03-20 Nutricia Nv Nutritional formulation with high energy content
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
WO2009072889A1 (en) * 2007-12-07 2009-06-11 N.V. Nutricia Bifidobacterium for dust mite allergy
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CN101951794B (en) * 2007-12-21 2016-11-02 N.V.努特里奇亚 Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota
PT2123168E (en) * 2008-05-16 2012-03-28 Nestec Sa Lactobacillus paracasei and weight control
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
EP3326633A1 (en) * 2008-06-13 2018-05-30 N.V. Nutricia Immune system stimulating nutrition
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
CN101768559B (en) * 2008-12-31 2012-03-07 生展生物科技股份有限公司 Lactobacillus, paracasei subsp. paracasei strain, bacteriostatic composition and applications thereof
SG10201901259RA (en) * 2009-02-24 2019-03-28 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
US8785160B2 (en) * 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
ATE546149T1 (en) * 2009-05-11 2012-03-15 Nestec Sa PREVENTION AND TREATMENT OF ALLERGIC DIARRHEA
ITMI20091034A1 (en) * 2009-06-11 2010-12-12 Parmalat Spa PROBIOTIC SPECIES OF BIFIDOBACTERIUM BREVE
DK3181134T3 (en) * 2009-06-19 2020-01-20 Dupont Nutrition Biosci Aps BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
EP3248605A1 (en) 2009-07-06 2017-11-29 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
IN2012DN00282A (en) * 2009-07-31 2015-05-08 Nestec Sa
DK2478910T3 (en) * 2009-09-17 2017-12-04 Morinaga Milk Industry Co Ltd ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE
EP2308498A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
WO2011071367A1 (en) * 2009-12-11 2011-06-16 N.V. Nutricia Metabolic imprinting effects of structured lipids
FR2955774A1 (en) 2010-02-02 2011-08-05 Aragan PREPARATION FOR TREATING PONDERAL EXCES AND ASSOCIATED DISORDERS AND APPLICATIONS THEREOF
WO2011149335A1 (en) * 2010-05-25 2011-12-01 N.V. Nutricia Immune imprinting nutritional composition
IT1405395B1 (en) * 2010-08-05 2014-01-10 Proge Farm Srl COMPOSITIONS OF PROBIOTICS AND OILS AND THEIR USE.
ITMI20110791A1 (en) 2011-05-09 2012-11-10 Probiotical Spa BACTERIA OF BACTERIA ABLE TO METABOLIZE THE OXALATES.
ITMI20110793A1 (en) * 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF PROBIOTIC BACTERIA AND SYNBIOTIC COMPOSITION CONTAINING THEMSELVES INTENDED FOR THE BABY FOOD.
ITMI20110792A1 (en) 2011-05-09 2012-11-10 Probiotical Spa STRAINS OF BACTERIA BELONGING TO THE BIFIDOBACTERIUM TYPE FOR USE IN THE TREATMENT OF HYPERCOLESTEROLEMIA.
ES2677850T3 (en) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
EP2729559B1 (en) * 2011-07-06 2018-08-22 DuPont Nutrition Biosciences ApS Method for reducing the viscosity of a microorganism-containing suspension or concentrate
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
ITMI20111718A1 (en) 2011-09-23 2013-03-24 Probiotical Spa A WATERPROOF MOISTURE AND OXYGEN MATERIAL FOR PACKAGING DIETARY, COSMETIC AND MEDICINAL PRODUCTS.
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
FI20116008A0 (en) * 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Prevention and diagnosis of visceral fat
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
KR20150118084A (en) * 2012-09-20 2015-10-21 프로테라 인코포레이티드 Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
ES2884223T3 (en) * 2012-11-02 2021-12-10 Nutricia Nv Combination of symbiotics for brain enhancement
WO2014130789A1 (en) 2013-02-21 2014-08-28 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
EP2994150B1 (en) 2013-05-10 2019-03-06 H.J. Heinz Company Brands Llc Probiotics and methods of use
ITMI20130793A1 (en) 2013-05-14 2014-11-15 Probiotical Spa COMPOSITION INCLUDING LACTIC BACTERIA FOR USE IN THE PREVENTIVE AND / OR CURATIVE TREATMENT OF THE RECURRENT CYCLES.
WO2016013928A1 (en) 2014-07-24 2016-01-28 N.V. Nutricia Prevention or treatment of food allergy in infants and toddlers
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
EA202090948A1 (en) 2014-12-23 2020-11-30 4Д Фарма Рисерч Лимитед IMMUNOMODULATION
PT3193901T (en) 2014-12-23 2018-06-29 4D Pharma Res Ltd Pirin polypeptide and immune modulation
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
ME03595B (en) 2015-06-15 2020-07-20 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2748812T3 (en) 2015-06-15 2020-03-18 4D Pharma Res Ltd Compositions comprising bacterial strains
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
LT3209310T (en) 2015-11-20 2018-04-25 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
BR112018067689A2 (en) 2016-03-04 2019-01-08 4D Pharma Plc compositions comprising bacterial strains of the genus blautia to treat visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
CN109561723A (en) * 2016-08-04 2019-04-02 雀巢产品技术援助有限公司 For preventing, treating the alimentation composition and infant formula of the mixture comprising oligosaccharide and optionally bifidobacterium lactis of non-rotavirus induced diarrhea or reduction its severity
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48941A (en) 2017-05-22 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
TW201907931A (en) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 Composition comprising a bacterial strain
SI3638271T1 (en) 2017-06-14 2021-01-29 4D Pharma Research Limited Compositions comprising bacterial strains
PL3600363T3 (en) 2017-06-14 2021-06-14 4D Pharma Research Limited Compositions comprising bacterial strains
EP3804737B1 (en) 2017-06-14 2022-05-18 4D Pharma Research Limited Compositions comprising bacterial strains
EP3645025B1 (en) * 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing atherosclerosis
EP4159224A1 (en) 2017-06-30 2023-04-05 N.V. Nutricia Synbiotic composition for preventing chronic inflammation
EP3749328A1 (en) * 2018-02-09 2020-12-16 N.V. Nutricia Fermented formula with non-digestible oligosaccharides
CN111954536A (en) * 2018-03-23 2020-11-17 森永乳业株式会社 Composition for infants and young children for preventing diseases caused by hyperglycemia in school age and later
US20240307465A1 (en) * 2020-11-24 2024-09-19 Johnson & Johnson Consumer Inc. Methods of preventing, delaying or ameliorating atopic diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN881396A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
JP4008974B2 (en) 1996-12-12 2007-11-14 森永乳業株式会社 Bifidobacterium growth promoting composition and use thereof
ATE208205T1 (en) * 1997-07-05 2001-11-15 Nestle Sa LACTOBACILLI TO INCREASE MINERAL ABSORPTION BY INTESTINAL CELLS
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
NL1010770C2 (en) 1998-12-09 2000-06-13 Nutricia Nv Preparation containing oligosaccharides and probiotics.
EP1175905A1 (en) * 2000-07-24 2002-01-30 Societe Des Produits Nestle S.A. Nutritional Composition
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
FI109602B (en) * 2001-01-25 2002-09-13 Valio Oy Probiotkombination
CN1164186C (en) * 2001-04-29 2004-09-01 上海光明乳业股份有限公司 Milk with probiotics and its production process
DE10206995B4 (en) 2002-02-19 2014-01-02 Orthomol Pharmazeutische Vertriebs Gmbh Micronutrient combination product with pro- and prebiotics
ITMI20020399A1 (en) * 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND / OR ANIMAL USE BASED ON MICROBIAL PROBIOTIC PREPARATIONS
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
EP1374878A1 (en) 2002-06-20 2004-01-02 N.V. Nutricia Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
CN1212068C (en) * 2002-11-13 2005-07-27 上海光明乳业股份有限公司 Immune formula milk powder and preparation process thereof
EP1481681A1 (en) * 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
EP2033529B1 (en) * 2003-10-24 2019-12-11 N.V. Nutricia Synbiotic composition for infants

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103054048A (en) * 2005-12-23 2013-04-24 纽崔西亚公司 Infant nutritional compositions for preventing obesity
US20100063002A1 (en) * 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
US20110014167A1 (en) * 2007-07-06 2011-01-20 N.V. Nutricia Use of probiotics and fibers for diarrhoea
US20120269789A1 (en) * 2009-05-11 2012-10-25 Nestec S.A. Growing up milks containing probiotic micro-organisms

Also Published As

Publication number Publication date
DK2351492T3 (en) 2014-12-01
CN104223094A (en) 2014-12-24
TR201820329T4 (en) 2019-01-21
RU2422025C2 (en) 2011-06-27
AU2006217160A1 (en) 2006-08-31
EP1855550A2 (en) 2007-11-21
CA2598961A1 (en) 2006-08-31
EP2351492B1 (en) 2014-08-20
EP2351492A1 (en) 2011-08-03
ES2524344T3 (en) 2014-12-05
US20160206667A1 (en) 2016-07-21
AU2006217160B2 (en) 2011-09-15
DK1855550T3 (en) 2012-01-16
US10071125B2 (en) 2018-09-11
EP1855550B1 (en) 2011-10-05
RU2007135869A (en) 2009-04-10
PL2805625T3 (en) 2019-04-30
RU2595396C2 (en) 2016-08-27
MX2007010466A (en) 2007-10-11
ZA200706875B (en) 2008-11-26
US20090004164A1 (en) 2009-01-01
WO2006091103A2 (en) 2006-08-31
PT1855550E (en) 2012-01-16
EP2805625A2 (en) 2014-11-26
BRPI0607743A2 (en) 2010-03-16
WO2006091103A3 (en) 2006-10-26
ES2702631T3 (en) 2019-03-04
PT2351492E (en) 2014-12-02
BRPI0607743B1 (en) 2020-09-15
EP2805625B1 (en) 2018-10-03
RU2011110056A (en) 2012-09-27
US9314047B2 (en) 2016-04-19
PL1855550T3 (en) 2012-03-30
ES2373971T3 (en) 2012-02-10
ES2702631T5 (en) 2023-03-22
PL2351492T3 (en) 2015-02-27
EP2805625A3 (en) 2015-03-25
CA2598961C (en) 2016-09-13
ATE526836T1 (en) 2011-10-15
CN101128129A (en) 2008-02-20
EP2805625B2 (en) 2022-11-23
PL2805625T5 (en) 2023-03-13

Similar Documents

Publication Publication Date Title
US20060194241A1 (en) Lactobacillus specific probes
Tannock Identification of lactobacilli and bifidobacteria
Fujimoto et al. Identification and quantification of Lactobacillus casei strain Shirota in human feces with strain-specific primers derived from randomly amplified polymorphic DNA
Haarman et al. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula
Jackson et al. Comparison of two selective media for the detection and enumeration of Lactobacilli in human faeces
Furet et al. Molecular quantification of lactic acid bacteria in fermented milk products using real-time quantitative PCR
Brigidi et al. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption
EP1997906A1 (en) Lactobacillus
Yeung et al. Species-specific identification of commercial probiotic strains
Macfarlane et al. Bacterial diversity in the human gut
EP1997907A1 (en) Bifidobacteria
Fujimoto et al. Quantitative detection of viable Bifidobacterium bifidum BF-1 cells in human feces by using propidium monoazide and strain-specific primers
Uyeno et al. Impact of consumption of probiotic lactobacilli-containing yogurt on microbial composition in human feces
Rochet et al. Effects of orally administered Lactobacillus casei DN-114 001 on the composition or activities of the dominant faecal microbiota in healthy humans
US20080274085A1 (en) Probiotic Bifidobacterial Species
Kao et al. Identification of Lactobacillus spp. in probiotic products by real-time PCR and melting curve analysis
Maruo et al. Monitoring the cell number of Lactococcus lactis subsp. cremoris FC in human feces by real-time PCR with strain-specific primers designed using the RAPD technique
Firmesse et al. Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction
Duary et al. Expression of the atpD gene in probiotic Lactobacillus plantarum strains under in vitro acidic conditions using RT-qPCR
Kim et al. Development of rapid and highly specific TaqMan probe-based real-time PCR assay for the identification and enumeration of Lactobacillus kefiri in kefir milk
KR102334331B1 (en) Real time pcr primers for detection of bifidobacterium species, and use thereof
Firmesse et al. Fate and effects of Camembert cheese micro-organisms in the human colonic microbiota of healthy volunteers after regular Camembert consumption
Cleusix et al. Comparative study of a new quantitative real‐time PCR targeting the xylulose‐5‐phosphate/fructose‐6‐phosphate phosphoketolase bifidobacterial gene (xfp) in faecal samples with two fluorescence in situ hybridization methods
Demkin et al. A novel real-time PCR assay for highly specific detection and quantification of vaginal lactobacilli
Vaugien et al. Bifidobacteria identification based on 16S rRNA and pyruvate kinase partial gene sequence analysis

Legal Events

Date Code Title Description
AS Assignment

Owner name: N.V. NUTRICIA, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNOL, JAN;HAARMAN, MONIQUE;REEL/FRAME:017591/0111;SIGNING DATES FROM 20060309 TO 20060313

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION